SoftOx Solutions AS
OSE:SOFTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.7), the stock would be worth kr0.08 (24% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | kr0.1 |
0%
|
| 3-Year Average | 1.7 | kr0.08 |
-24%
|
| 5-Year Average | 2.4 | kr0.11 |
+5%
|
| Industry Average | 4.3 | kr0.2 |
+91%
|
| Country Average | 1.7 | kr0.08 |
-25%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| NO |
S
|
SoftOx Solutions AS
OSE:SOFTX
|
233.9m NOK | 2.2 | -15.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 31.5 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 5.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 1.8 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 6.4 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 1.7 |
| 70th Percentile | 3.3 |
| Max | 234.8 |
Other Multiples
SoftOx Solutions AS
Glance View
SoftOx Solutions AS engages in research and product development. The company is headquartered in Fornebu, Akershus. The company went IPO on 2018-06-01. The company is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOx’s product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The firm has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.
